Abstract：Ebola virus is an extremely important pathogen threat to the global public health and one of the toxic species of the terrorist attacks, it was classified as the potential biological agent of warfare and the most serious harm to human by WHO. The pathogenic features,host immune response and laboratory diagnosis are the key points for the patient’s early discovery, isolate and therapy. In this paper, we review to provide a reference for the further prevention and control of Ebola disease.
[1] Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg andEbola viruses[M]. In: Knipe DM, Howley PM, eds. Fields virology.Philadelphia: Lippincott Williams & Wilkins, 2006,1409-1448. [2] Feldmann H, Geisbert TW.Ebola haemorrhagic fever. TheSee comment in PubMed Commons belowLancet, 2011, 377(9768):849-62. [3] WHO. Ebola haemorrhagic fever in Sudan, 1976.Bull World Health Organ,1978, 56: 247-70. [4] 李昱, 任翔, 刘翟, 等.埃博拉病毒病: 流行病学、生态学、诊断、治疗及控制[J].科技导报, 2014, 32(24): 15-24. [5] http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html [6] http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/ [7] Kiley MP, Bowen ET, Eddy GA, et al. Filoviridae: a taxonomic homefor Marburg and Ebola viruses[J]? Intervirology, 1982, 18: 24-32. [8] Feldmann H. Ebola-A Growing Threat[J].N Engl J Med 2014, 371:1375-1378. [9] Muhlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems [J]. J Virol 1999,73: 2333-2342. [10] Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35protein functions as a type I IFN antagonist[J]. Proc Natl Acad Sci 2000, 97: 12289-12294. [11] Cheng Y, Li Y, Yu HJ. Ebola virus disease: general characteristics, thoughts, and perspectives [J].Biomed Environ Sci, 2014, 27(8): 651-653. [12] Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP[J].J Virol 2002,76: 4855-4865. [13] Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation[J].J Virol 2006, 80: 5156-5167. [14] Siegert R, Shu HL, Slenczka W, et al. On the etiology of an unknown human infection originating from monkeys[J]. Dtsch Med Wochenschr 1967, 92: 2341-2343. [15] WHO. Ebola haemorrhagic fever in Sudan, 1976[J].Bull World Health Organ 1978, 56: 247-270. [16] WHO. Ebola haemorrhagic fever in Zaire, 197[J]6.Bull World Health Organ 1978, 56: 271-293. [17] Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus[J]. The Lancet 1995,345: 1271-1274. [18] Wamala JF, Lukwago L, Malimbo M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007—2008[J]. Emerg Infect Dis, 2010, 16(7): 1087-1092. [19] Jahrling PB, Geisbert TW, Johnson ED, et al. Preliminary report: Isolation of Ebola virus from monkeys imported to USA[J]. The Lancet,1990, 335: 502-505. [20] Barrette R W, Metwally S A, Rowland J M, et al. Discovery of swine as a host for the Reston ebola virus [J]. Science, 2009, 325: 204-206. [21] Miranda ME, White ME, Dayrit MM, et al. Seroepidemiological study of filovirus related to Ebola in the Philippines. [J]. The Lancet, 1991,337: 425-426. [22] Pan YY, Zhang W, Cui L, et al. Reston virus in domestic pigs in China[J].Arch Virol, 2014, 159(5):1129-1132. [23] Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola haemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection[J].Am J Pathol 2003,163: 2347-2370. [24] Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection[J]. J Infect Dis 1999, 179 : S188-191. [25] Heinz F, Thomas W G. Ebola haemorrhagic fever[J]. The Lancet, 2011,377: 849-862. [26] Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea [J].N Engl J Med, 2015, 372:40-47. [27] WHO, Laboratory diagnosis of Ebola virus disease. 19 September 2014. ( http://apps.who.int/iris/bitstream/10665/134009/1/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf) [28] Gire SK, Goba A, Andersen KG,et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak[J]. Science. 2014,345(6202):1369-1372. [29] 埃博拉出血热实验室检测方案（第三版,2014年11月5日）,中国疾病预防控制中心. [30] Kreuels B, Wichmann D, Emmerich P,et al. A case of severe Ebola virus infection complicated by gram-negative septicemia[J]. N Engl J Med. 2014,371(25):2394-2401. (https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/406062/ 31 PHE_Microbiology_Services_VHF_Sample_Testing_Advice_200215.pdf) [32] Guidance for Collection, Transport and Submission of Specimens for Ebola Virus Testing.(http://www.cdc.gov/vhf/ebola/healthcare-us/laboratories/specimens.html) [33] Guidance on regulationsfor theTransport of Infectious Substances.(http://apps.who.int/iris/bitstream/10665/78075/1/WHO_HSE_GCR_2012.12_eng.pdf?ua=1) [34] Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola Virus Diseasein Guinea[J]. N Engl J Med 2014,371:1418-1425. [35] 程颖,刘军,李昱,等.埃博拉病毒病：病原学、致病机制、治疗与疫苗研究进展[J].科学通报,2014,59 (30):2889-2899.
2015, Vol. 22 
